drugset / Trial / NCT04623710
Study of ALXN2050 in Participants With Renal Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.
Timeline
- Start
- 2021-07-08
- Primary completion
- 2022-02-18
- Completion
- 2022-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vemircopan | Small molecule | 120 mg | Oral |